Harmony Biosciences Holdings (HRMY)

Currency in USD
37.45
+0.03(+0.08%)
Real-time Data·
HRMY Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
HRMY is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
37.1037.52
52 wk Range
26.4741.61
Key Statistics
Prev. Close
37.42
Open
37.41
Day's Range
37.1-37.52
52 wk Range
26.47-41.61
Volume
8.78K
Average Volume (3m)
602.24K
1-Year Change
2.92%
Book Value / Share
13.46
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HRMY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
50.55
Upside
+34.97%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings downwards for the upcoming period
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Harmony Biosciences Holdings Company Profile

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company’s products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Employees
268

Harmony Biosciences Holdings Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of $0.92 beat expectations by 27.78%, but revenue of $200.5M missed forecasts; stock fell 3.88% pre-market
  • Revenue grew 16% YoY; company maintains strong cash position of $672M and generated $79M from operations in Q2
  • Wakix patient base increased by 400; full-year revenue guidance reaffirmed at $820M-$860M
  • Key catalysts ahead: ZYN-two Phase III data for Fragile X syndrome, initiation of Pitolacin HD Phase III trials
  • CEO emphasized profitability and self-funding status; company targets potential peak sales of $3-6B
Last Updated: 05/08/2025, 18:24
Read Full Transcript

Compare HRMY to Peers and Sector

Metrics to compare
HRMY
Peers
Sector
Relationship
P/E Ratio
11.9x−8.0x−0.6x
PEG Ratio
0.20−0.510.00
Price/Book
2.8x8.2x2.6x
Price / LTM Sales
2.8x1.7x3.3x
Upside (Analyst Target)
31.0%69.7%39.0%
Fair Value Upside
Unlock13.1%4.9%Unlock

Analyst Ratings

9 Buy
1 Hold
1 Sell
Ratings:
11 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 50.55
(+34.97% Upside)

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
0.92 / 0.72
Revenue / Forecast
200.50M / 204.59M
EPS Revisions
Last 90 days

HRMY Income Statement

People Also Watch

38.07
EXEL
+0.44%
465.94
MEDP
-0.18%
188.99
IQV
+0.52%
35.86
YOU
-0.47%
306.68
UNH
+0.60%

FAQ

What Stock Exchange Does Harmony Bio Trade On?

Harmony Bio is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Harmony Bio?

The stock symbol for Harmony Bio is "HRMY."

What Is the Harmony Bio Market Cap?

As of today, Harmony Bio market cap is 2.14B.

What Is Harmony Bio's Earnings Per Share (TTM)?

The Harmony Bio EPS (TTM) is 3.16.

When Is the Next Harmony Bio Earnings Date?

Harmony Bio will release its next earnings report on 03 Nov 2025.

From a Technical Analysis Perspective, Is HRMY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Harmony Bio Stock Split?

Harmony Bio has split 0 times.

How Many Employees Does Harmony Bio Have?

Harmony Bio has 268 employees.

What is the current trading status of Harmony Bio (HRMY)?

As of 26 Aug 2025, Harmony Bio (HRMY) is trading at a price of 37.45, with a previous close of 37.42. The stock has fluctuated within a day range of 37.10 to 37.52, while its 52-week range spans from 26.47 to 41.61.

What Is Harmony Bio (HRMY) Price Target According to Analysts?

The average 12-month price target for Harmony Bio is USD50.54545, with a high estimate of USD70 and a low estimate of USD31. 9 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +34.97% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.